ExLibris header image
SFX Logo
Title: Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma
Source:

Blood [0006-4971] Polson, Andrew yr:2007


Collapse list of basic services Basic
Sorry, no full text available...
Please use the document delivery service (see below)  
Holding information
Holdings in library search engine ALBERT GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Phillips, G. "Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate." Cancer research 68.22 (2008): 9280-9290. Link to SFX for this item
2. Doronina, Svetlana O. "Development of potent monoclonal antibody auristatin conjugates for cancer therapy." Nature biotechnology 21.7 (2003): 778-84. Link to Full Text for this item Link to SFX for this item
3. Floss, Doreen Manuela M. "Production of vaccines and therapeutic antibodies for veterinary applications in transgenic plants: an overview." Transgenic research 16.3 (2007): 315-332. Link to Full Text for this item Link to SFX for this item
4. Webb, S. "Pharma interest surges in antibody drug conjugates." Nature biotechnology 29.4 (2011): 297-298. Link to SFX for this item
5. Yang, J. "Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging." Proceedings of the National Academy of Sciences of the United States of America 103.37 (2006): 13872-13877. Link to Full Text for this item Link to SFX for this item
6. Holliger, P. "Engineered antibody fragments and the rise of single domains." Nature biotechnology 23.9 (2005): 1126-36. Link to Full Text for this item Link to SFX for this item
7. Verma, S. "Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer." The New England journal of medicine 367.19 (2012): 4294967295-1791. Link to SFX for this item
8. LoRusso, Patricia M. "Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer." Clinical cancer research 17.20 (2011): 6437-6447. Link to SFX for this item
9. Chattopadhyay, N. "Design and Characterization of HER-2-Targeted Gold Nanoparticles for Enhanced X-radiation Treatment of Locally Advanced Breast Cancer." Molecular pharmaceutics 7.6 (2010): 2194-2206. Link to Full Text for this item Link to SFX for this item
10. Luesch, H. "Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1." Journal of natural products 64.7 (2001): 907-910. Link to Full Text for this item Link to SFX for this item
11. Rodon, J. "Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study." Cancer chemotherapy and pharmacology 62.5 (2008): 911-919. Link to Full Text for this item Link to SFX for this item
12. Guerrero-Andrade, O.. "Expression of the Newcastle disease virus fusion protein in transgenic maize and immunological studies." Transgenic research 15.4 (2006): 455-463. Link to Full Text for this item Link to SFX for this item
13. Trail, PA, Pamela A A. "Monoclonal antibody drug immunoconjugates for targeted treatment of cancer." Cancer immunology, immunotherapy 52.5 (2003): 328-337. Link to Full Text for this item Link to SFX for this item
14. Yang, J. "Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates." The Journal of pharmacology and experimental therapeutics 321.2 (2007): 462-468. Link to SFX for this item
15. Gumbleton Mark, M. "Coming out of the dark: the evolving role of fluorescence imaging in drug delivery research." Advanced Drug Delivery Reviews 57.1 (2005): 5-15. Link to SFX for this item
16. Leamon, Christopher P. "Synthesis and Biological Evaluation of EC140: A Novel Folate-Targeted Vinca Alkaloid Conjugate." Bioconjugate chemistry 17.5 (2006): 1226-1232. Link to Full Text for this item Link to SFX for this item
17. Chari, R. "Targeted cancer therapy: Conferring specificity to cytotoxic drugs." Accounts of chemical research 41.1 (2008): 98-107. Link to Full Text for this item Link to SFX for this item
18. Bradbury, Andrew R. "Beyond natural antibodies: the power of in vitro display technologies." Nature biotechnology 29.3 (2011): 245-254. Link to SFX for this item
19. Igawa, T. "Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization." Nature biotechnology 28.11 (2010): 1203-1207. Link to SFX for this item
20. Castanotto, D. "The promises and pitfalls of RNA-interference-based therapeutics." Nature 457.7228 (2009): 426-433. Link to Full Text for this item Link to SFX for this item
View More...
View Less...
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.